Expedited PublicationSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Stone has served on the scientific advisory board for Boston Scientific and Abbott Vascular, and has received honoraria from BMS-Sanofi, AstraZeneca, and The Medicines Company. Dr. Witzenbichler has received lecture honoraria from The Medicines Company and Boston Scientific. Dr. Kirtane has served as a consultant to Abbott Vascular, Boston Scientific, and Medtronic. Dr. Guagliumi has received consulting fees from Boston Scientific, lecture honoraria from The Medicines Company and Medtronic, and grant support from Medtronic, Boston Scientific, and Labcoat. Dr. Brodie is on the Speakers' Bureau for The Medicines Company and Medtronic. Dr. Dudek has received consulting and lecture honoraria from Abbott, Adamed, Biotronik, Balton, Bayer, BBraun, BioMatrix, Boston Scientific, Boehringer Inc., Bristol-Myers Squibb, Cordis, Cook, Eli Lilly, EuroCor, Glaxo, Invatec, Medtronic, The Medicines Company, MSD, Nycomed, Orbus-Neich, Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Dr. Möckel has received consulting and lecture honoraria from The Medicines Company. Dr. Lanksy has received research support from Boston Scientificand The Medicines Company. Dr. Mehran reports having received consulting fees from Bristol-Myers Squibb/Sanofi, Medtronic, and The Medicines Company. All other authors have reported that they have no relationships to disclose.